Case 1:20-cv-00393-LMB-WEF Document 1462-19 Filed 04/05/23 Page 1 of 14 PageID# 39735

Exhibit 19 Public Redacted Version

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>. Case 1:20-cv-00393-LMB-WEF Document 1462-19 Filed 04/05/23 Page 2 of 14 PageID# 39736 Confidential-Subject to Protective Order

UNITED STATES INTERNATIONAL TRADE COMMISSION WASHINGTON, D.C.

In the Matter of

Δ

CERTAIN TOBACCO HEATING ARTICLES AND COMPONENTS

THEREOF

Inv. No. 337-TA-1199

EXPERT REPORT OF JONATHAN ARNOLD, PH.D.

CONFIDENTIAL

Case 1:20-cv-00393-LMB-WEF Document 1462-19 Filed 04/05/23 Page 3 of 14 PageID# 39737 Confidential-Subject to Protective Order

III. SUMMARY OF OPINIONS

12. Based on my analysis to date, as well as my skill, knowledge, education, experience, and training, I have formed the following opinions:

- <u>Domestic Industry</u>. Dr. Mody's assessment of Complainants'

 investment in plant and equipment, (ii) investment in
 labor or capital, and (iii) exploitation of the patents for VUSE
 Solo (Generation 1 and 2) and VUSE Vibe is fundamentally
 flawed for at least two reasons: her analysis (1) disregards
 the factual record in this matter and (2) depends on
 unsupported assumptions that have a material effect on her
 opinions.
- <u>Public Interest</u>. Dr. Mody is incorrect that the public's interest would be unharmed by an exclusion order. Her opinion hinges on her assertation that e-cigarettes, IQOS® and other PRRPs are substitutes; however, the analysis Dr. Mody undertakes is flawed and unreliable. To the contrary, substantial evidence suggests that IQOS® is a differentiated product from other PRRPs and provides features to consumers that other PRRPs do not. As such, an exclusion order for IQOS® would adversely affect the public interest by depriving consumers of a differentiated product.
- <u>Public Health and Welfare</u>. Dr. Mody claims that the granting of an exclusion order would not have a negative impact on public health and welfare. To the contrary, if no exclusion were to issue, then a percentage of combustible cigarette smokers would likely transition to IQOS® use, thereby avoiding the harmful effects of combustible cigarette smoke. Even if only a relatively small percentage of

Case 1:20-cv-00393-LMB-WEF Document 1462-19 Filed 04/05/23 Page 4 of 14 PageID# 39738 Confidential-Subject to Protective Order

direct comparison of product pricing when she asserts that IQOS® has been "launched domestically with a pricing strategy intended to compete with other non-combustible products."¹³⁰ In other words, in attempting to define the market, Dr. Mody implies that IQOS® is priced similarly to the VUSE products and are therefore in the same market and should be considered substitutes.

99. On the other hand, in her bond analysis she argues that "a direct comparison of product pricing in this case is not meaningful."¹³¹ Then based on a perpuff analysis (a cost measure Dr. Mody establishes without basis) of VUSE Solo and IQOS® she concludes that the cost of IQOS® is approximately **Constant of the transformed and the text** that the cost of the VUSE products.¹³² (Based on this she concludes that a bond should be set at 100 percent – an opinion with which I disagree and which I address in Section IX.)

100. Dr. Mody cannot have it both ways. If IQOS® and the VUSE products are similarly priced, then her bond analysis must be wrong. If one accepts her bond analysis then her assertions regarding the market definition must be wrong.¹³³

C. Dr. Mody's Own Evidence Shows that IQOS® and other PRRPs are Differentiated

101. Dr. Mody selects quotes out of a variety of documents to attempt to establish that IQOS® and e-cigarettes are substitute products within the PRRP market. However, if one reviews Dr. Mody's cherry-picked quotes in their context, these documents reveal that multiple consumer groups in the U.S. markets consider IQOS® to be differentiated from other non-combustible products.

Find authenticated court documents without watermarks at docketalarm.com.

¹³⁰ Mody Report, p. 50.

¹³¹ Mody Report, p. 102.

¹³² Mody Report, p. 104.

¹³³ I make this point to show that, using the internal logic of Dr. Mody's report, both opinions cannot coexist. As it turns out, neither opinion is correct – for a variety of other reasons that I address throughout this report.

Case 1:20-cv-00393-LMB-WEF Document 1462-19 Filed 04/05/23 Page 5 of 14 PageID# 39739 Confidential-Subject to Protective Order

i. Market Participants View IQOS® and E-Cigarettes as Differentiated Products

102. Dr. Mody cites to certain quotes from industry analysts and experts that "[define] the relevant market as larger than HNB products."¹³⁴ However, Dr. Mody fails to acknowledge that the documents she cites also discuss the ways in which IQOS® is differentiated from other PRRPs. As I explain above, if IQOS® and other PRRPs are close substitutes, IQOS® could build market share only (or predominantly) by competing on price. If, however, IQOS® and other PRRPs are differentiated (i.e., imperfect substitutes), IQOS® may also build market share by attracting combustible cigarette consumers who prefer certain features of the IQOS® over other PRRPs. Exhibit 10 below details some examples of market reaction to the launch of IQOS® in the U.S.

Find authenticated court documents without watermarks at docketalarm.com.

¹³⁴ Mody Report, p. 43.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.